Metacam, Boehringer Ingelheim Animal Health's leading brand in the control of inflammatory processes has obtained marketing authorization in all EU countries for treatment of pigs and dairy cows. For pigs, Metacam has received this additional approval for the treatment of Mastitis Metritis Agalactia (MMA) and non-infectious locomoter disorders. For dairy cows treatment of mastitis has been approved.

In registration studies for swine, Metacam demonstrated a significant and lasting efficacy in controlling inflammatory processes in sows suffering from MMA. Litters of affected sows were found to show lower mortality rates when treated with Metacam. Symptoms of lameness were significantly reduced in Metacam treated pigs. The animals were also shown to return to feed more quickly; normal behaviour and well-being were restored more rapidly.

For dairy cows, Metacam was shown, with a single administration, to significantly and sustainably reduce clinical symptoms with a single administration in naturally occurring acute mastitis, caused by key pathogens E. coli, Strep. uberis and Staph. aureus.

The exceptional efficacy of Metacam in controlling the effects of endotoxins, as found in sow's MMA and cow's mastitis, was confirmed.

Metacam has been marketed since 1993 in companion animals and since 1998 in cattle. The new indications for swine and dairy cows reconfirm the broad spectrum of applicability of Metacam as a highly effective tool in the control of inflammatory processes, while exhibiting an excellent tolerance in and safety for animals.

By continuing to complete the range of indications for Metacam, Boehringer Ingelheim continues to support veterinarians and farmers in maintaining and improving profitability, animal health and well being in livestock farming.